Cargando...
Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with (18)F-FDOPA and (18)F-FDG PET
Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necess...
Gardado en:
| Publicado en: | J Nucl Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Society of Nuclear Medicine
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6167538/ https://ncbi.nlm.nih.gov/pubmed/29700126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.208744 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|